nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—multiple sclerosis	0.491	1	CbGaD
Gliclazide—ALB—Prednisone—multiple sclerosis	0.0439	0.346	CbGbCtD
Gliclazide—CYP2C19—Prednisone—multiple sclerosis	0.0284	0.224	CbGbCtD
Gliclazide—ALB—Methotrexate—multiple sclerosis	0.022	0.173	CbGbCtD
Gliclazide—CYP2C19—Dexamethasone—multiple sclerosis	0.0178	0.14	CbGbCtD
Gliclazide—CYP2C9—Dexamethasone—multiple sclerosis	0.0148	0.116	CbGbCtD
Gliclazide—Chlorpropamide—SLC15A2—multiple sclerosis	0.00237	0.358	CrCbGaD
Gliclazide—Tolbutamide—SLC15A2—multiple sclerosis	0.00231	0.349	CrCbGaD
Gliclazide—Glyburide—SLC15A2—multiple sclerosis	0.0016	0.242	CrCbGaD
Gliclazide—VEGFA—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000615	0.105	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Methylprednisolone—multiple sclerosis	0.000615	0.105	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Betamethasone—multiple sclerosis	0.000605	0.104	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Dexamethasone—multiple sclerosis	0.000605	0.104	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Triamcinolone—multiple sclerosis	0.000591	0.101	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Triamcinolone—multiple sclerosis	0.000591	0.101	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—multiple sclerosis	0.000561	0.0961	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisone—multiple sclerosis	0.000561	0.0961	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisolone—multiple sclerosis	0.000548	0.0938	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisolone—multiple sclerosis	0.000548	0.0938	CbGdCrCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000386	0.00365	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL2—multiple sclerosis	0.000356	0.00337	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ITGA4—multiple sclerosis	0.000344	0.00326	CbGpPWpGaD
Gliclazide—Glyburide—ALB—multiple sclerosis	0.000344	0.052	CrCbGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000343	0.00324	CbGpPWpGaD
Gliclazide—VEGFA—Heart Development—MAPK1—multiple sclerosis	0.00034	0.00322	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—ALB—multiple sclerosis	0.00034	0.00321	CbGpPWpGaD
Gliclazide—ALB—Lipoprotein metabolism—APOE—multiple sclerosis	0.000336	0.00317	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000335	0.00317	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000328	0.0031	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000324	0.00306	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ALB—multiple sclerosis	0.000324	0.00306	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—TGFB1—multiple sclerosis	0.000323	0.00306	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—multiple sclerosis	0.000321	0.00304	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IFNG—multiple sclerosis	0.000313	0.00296	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000312	0.00295	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—multiple sclerosis	0.000312	0.00295	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PRNP—multiple sclerosis	0.000311	0.00294	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00031	0.00294	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000309	0.00293	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000309	0.00292	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PLEK—multiple sclerosis	0.000309	0.00292	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000293	0.00277	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—BCHE—multiple sclerosis	0.000291	0.00275	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000285	0.00269	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000285	0.00269	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—BCHE—multiple sclerosis	0.000282	0.00266	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000281	0.00265	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000281	0.00265	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL1B—multiple sclerosis	0.000279	0.00264	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL2—multiple sclerosis	0.000278	0.00263	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000275	0.0026	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—STAT3—multiple sclerosis	0.000274	0.00259	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL5—multiple sclerosis	0.000268	0.00253	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IFNB1—multiple sclerosis	0.000263	0.00248	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—TYK2—multiple sclerosis	0.000262	0.00248	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—multiple sclerosis	0.000261	0.00247	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000259	0.00245	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000259	0.00245	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—multiple sclerosis	0.000257	0.00243	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000256	0.00242	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000256	0.00242	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—MAPK1—multiple sclerosis	0.000255	0.00241	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—MAPK1—multiple sclerosis	0.000249	0.00235	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—TYK2—multiple sclerosis	0.000248	0.00234	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—SPP1—multiple sclerosis	0.000245	0.00232	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000245	0.00232	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IL6—multiple sclerosis	0.000244	0.0023	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PTPRC—multiple sclerosis	0.000242	0.00229	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—multiple sclerosis	0.00024	0.00227	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SRM—multiple sclerosis	0.000239	0.00226	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000236	0.00223	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SRM—multiple sclerosis	0.000231	0.00219	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000231	0.00219	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—multiple sclerosis	0.000229	0.00217	CbGpPWpGaD
Gliclazide—ALB—Lipid and lipoprotein metabolism—APOE—multiple sclerosis	0.000223	0.00211	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PRNP—multiple sclerosis	0.000222	0.0021	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	0.000219	0.00208	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SELE—multiple sclerosis	0.000218	0.00206	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—multiple sclerosis	0.000217	0.00205	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—multiple sclerosis	0.000215	0.00203	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	0.000211	0.002	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL4—multiple sclerosis	0.000211	0.002	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL6—multiple sclerosis	0.000209	0.00198	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	0.000208	0.00197	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	0.000206	0.00195	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	0.000205	0.00194	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000204	0.00193	CbGpPWpGaD
Gliclazide—Dermatitis—Azathioprine—multiple sclerosis	0.000204	0.000773	CcSEcCtD
Gliclazide—Depression—Methotrexate—multiple sclerosis	0.000204	0.000772	CcSEcCtD
Gliclazide—Flushing—Prednisone—multiple sclerosis	0.000204	0.000772	CcSEcCtD
Gliclazide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000203	0.000772	CcSEcCtD
Gliclazide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000203	0.000772	CcSEcCtD
Gliclazide—Discomfort—Triamcinolone—multiple sclerosis	0.000203	0.000771	CcSEcCtD
Gliclazide—Discomfort—Methylprednisolone—multiple sclerosis	0.000203	0.000769	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—TNF—multiple sclerosis	0.000203	0.00192	CbGpPWpGaD
Gliclazide—Headache—Azathioprine—multiple sclerosis	0.000203	0.000768	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000202	0.000768	CcSEcCtD
Gliclazide—Dry mouth—Triamcinolone—multiple sclerosis	0.000201	0.000763	CcSEcCtD
Gliclazide—Renal failure—Methotrexate—multiple sclerosis	0.000201	0.000762	CcSEcCtD
Gliclazide—Angioedema—Dexamethasone—multiple sclerosis	0.0002	0.00076	CcSEcCtD
Gliclazide—Angioedema—Betamethasone—multiple sclerosis	0.0002	0.00076	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—multiple sclerosis	0.000199	0.000753	CcSEcCtD
Gliclazide—Confusional state—Methylprednisolone—multiple sclerosis	0.000198	0.000753	CcSEcCtD
Gliclazide—Malaise—Dexamethasone—multiple sclerosis	0.000198	0.00075	CcSEcCtD
Gliclazide—Malaise—Betamethasone—multiple sclerosis	0.000198	0.00075	CcSEcCtD
Gliclazide—Arrhythmia—Prednisone—multiple sclerosis	0.000196	0.000743	CcSEcCtD
Gliclazide—Infection—Triamcinolone—multiple sclerosis	0.000196	0.000743	CcSEcCtD
Gliclazide—Sweating—Methotrexate—multiple sclerosis	0.000196	0.000743	CcSEcCtD
Gliclazide—Infection—Methylprednisolone—multiple sclerosis	0.000196	0.000742	CcSEcCtD
Gliclazide—Insomnia—Prednisolone—multiple sclerosis	0.000194	0.000736	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000193	0.000733	CcSEcCtD
Gliclazide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000193	0.000732	CcSEcCtD
Gliclazide—Loss of consciousness—Betamethasone—multiple sclerosis	0.000193	0.000731	CcSEcCtD
Gliclazide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000193	0.000731	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—multiple sclerosis	0.000193	0.000731	CcSEcCtD
Gliclazide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000193	0.000731	CcSEcCtD
Gliclazide—Paraesthesia—Prednisolone—multiple sclerosis	0.000193	0.000731	CcSEcCtD
Gliclazide—Tachycardia—Triamcinolone—multiple sclerosis	0.000193	0.00073	CcSEcCtD
Gliclazide—Mental disorder—Prednisone—multiple sclerosis	0.000192	0.000729	CcSEcCtD
Gliclazide—Nausea—Azathioprine—multiple sclerosis	0.000192	0.000729	CcSEcCtD
Gliclazide—Tachycardia—Methylprednisolone—multiple sclerosis	0.000192	0.000729	CcSEcCtD
Gliclazide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000191	0.000725	CcSEcCtD
Gliclazide—Erythema—Prednisone—multiple sclerosis	0.000191	0.000724	CcSEcCtD
Gliclazide—Malnutrition—Prednisone—multiple sclerosis	0.000191	0.000724	CcSEcCtD
Gliclazide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000191	0.000723	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000191	0.000723	CcSEcCtD
Gliclazide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00019	0.000722	CcSEcCtD
Gliclazide—Convulsion—Dexamethasone—multiple sclerosis	0.00019	0.000721	CcSEcCtD
Gliclazide—Convulsion—Betamethasone—multiple sclerosis	0.00019	0.000721	CcSEcCtD
Gliclazide—Hypertension—Dexamethasone—multiple sclerosis	0.000189	0.000718	CcSEcCtD
Gliclazide—Hypertension—Betamethasone—multiple sclerosis	0.000189	0.000718	CcSEcCtD
Gliclazide—Asthenia—Mitoxantrone—multiple sclerosis	0.000188	0.000711	CcSEcCtD
Gliclazide—Myalgia—Dexamethasone—multiple sclerosis	0.000187	0.000708	CcSEcCtD
Gliclazide—Myalgia—Betamethasone—multiple sclerosis	0.000187	0.000708	CcSEcCtD
Gliclazide—Anxiety—Betamethasone—multiple sclerosis	0.000186	0.000706	CcSEcCtD
Gliclazide—Anxiety—Dexamethasone—multiple sclerosis	0.000186	0.000706	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000186	0.00176	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	0.000184	0.00174	CbGpPWpGaD
Gliclazide—Discomfort—Betamethasone—multiple sclerosis	0.000184	0.0007	CcSEcCtD
Gliclazide—Discomfort—Dexamethasone—multiple sclerosis	0.000184	0.0007	CcSEcCtD
Gliclazide—Hypotension—Methylprednisolone—multiple sclerosis	0.000184	0.000698	CcSEcCtD
Gliclazide—Pain—Prednisolone—multiple sclerosis	0.000183	0.000696	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—multiple sclerosis	0.000183	0.000695	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—multiple sclerosis	0.000182	0.00069	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00018	0.000682	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000179	0.00068	CcSEcCtD
Gliclazide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000179	0.000679	CcSEcCtD
Gliclazide—Insomnia—Triamcinolone—multiple sclerosis	0.000178	0.000677	CcSEcCtD
Gliclazide—Insomnia—Methylprednisolone—multiple sclerosis	0.000178	0.000675	CcSEcCtD
Gliclazide—Infection—Betamethasone—multiple sclerosis	0.000178	0.000674	CcSEcCtD
Gliclazide—Infection—Dexamethasone—multiple sclerosis	0.000178	0.000674	CcSEcCtD
Gliclazide—Ill-defined disorder—Prednisone—multiple sclerosis	0.000177	0.000672	CcSEcCtD
Gliclazide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000177	0.000672	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000177	0.00067	CcSEcCtD
Gliclazide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000177	0.00067	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—multiple sclerosis	0.000177	0.00067	CcSEcCtD
Gliclazide—Anaemia—Prednisone—multiple sclerosis	0.000177	0.00067	CcSEcCtD
Gliclazide—ALB—Hemostasis—CD58—multiple sclerosis	0.000176	0.00167	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MERTK—multiple sclerosis	0.000176	0.00167	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SELPLG—multiple sclerosis	0.000176	0.00167	CbGpPWpGaD
Gliclazide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000176	0.000667	CcSEcCtD
Gliclazide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000176	0.000666	CcSEcCtD
Gliclazide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000176	0.000666	CcSEcCtD
Gliclazide—Agitation—Prednisone—multiple sclerosis	0.000175	0.000666	CcSEcCtD
Gliclazide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000175	0.000665	CcSEcCtD
Gliclazide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000175	0.000665	CcSEcCtD
Gliclazide—Tachycardia—Dexamethasone—multiple sclerosis	0.000175	0.000663	CcSEcCtD
Gliclazide—Tachycardia—Betamethasone—multiple sclerosis	0.000175	0.000663	CcSEcCtD
Gliclazide—Angioedema—Prednisone—multiple sclerosis	0.000175	0.000662	CcSEcCtD
Gliclazide—Dyspepsia—Triamcinolone—multiple sclerosis	0.000174	0.000659	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—multiple sclerosis	0.000173	0.000658	CcSEcCtD
Gliclazide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000173	0.000657	CcSEcCtD
Gliclazide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000173	0.000656	CcSEcCtD
Gliclazide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000173	0.000656	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—PTPRC—multiple sclerosis	0.000172	0.00163	CbGpPWpGaD
Gliclazide—Malaise—Prednisone—multiple sclerosis	0.000172	0.000653	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—multiple sclerosis	0.000171	0.00065	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—multiple sclerosis	0.000171	0.000648	CcSEcCtD
Gliclazide—Urticaria—Prednisolone—multiple sclerosis	0.00017	0.000646	CcSEcCtD
Gliclazide—Fatigue—Triamcinolone—multiple sclerosis	0.00017	0.000645	CcSEcCtD
Gliclazide—Fatigue—Methylprednisolone—multiple sclerosis	0.00017	0.000644	CcSEcCtD
Gliclazide—Pain—Triamcinolone—multiple sclerosis	0.000169	0.00064	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CYP27B1—multiple sclerosis	0.000168	0.00159	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP24A1—multiple sclerosis	0.000168	0.00159	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisone—multiple sclerosis	0.000168	0.000637	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—ICAM1—multiple sclerosis	0.000168	0.00159	CbGpPWpGaD
Gliclazide—Hypotension—Betamethasone—multiple sclerosis	0.000167	0.000634	CcSEcCtD
Gliclazide—Hypotension—Dexamethasone—multiple sclerosis	0.000167	0.000634	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—MAPK1—multiple sclerosis	0.000167	0.00158	CbGpPWpGaD
Gliclazide—Vomiting—Mitoxantrone—multiple sclerosis	0.000166	0.000631	CcSEcCtD
Gliclazide—Convulsion—Prednisone—multiple sclerosis	0.000165	0.000628	CcSEcCtD
Gliclazide—Hypertension—Prednisone—multiple sclerosis	0.000165	0.000625	CcSEcCtD
Gliclazide—Rash—Mitoxantrone—multiple sclerosis	0.000165	0.000625	CcSEcCtD
Gliclazide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000165	0.000625	CcSEcCtD
Gliclazide—Chills—Methotrexate—multiple sclerosis	0.000165	0.000624	CcSEcCtD
Gliclazide—Headache—Mitoxantrone—multiple sclerosis	0.000164	0.000621	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000163	0.000618	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000163	0.000618	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CYP27B1—multiple sclerosis	0.000163	0.00154	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP24A1—multiple sclerosis	0.000163	0.00154	CbGpPWpGaD
Gliclazide—Arthralgia—Prednisone—multiple sclerosis	0.000163	0.000617	CcSEcCtD
Gliclazide—Myalgia—Prednisone—multiple sclerosis	0.000163	0.000617	CcSEcCtD
Gliclazide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000163	0.000617	CcSEcCtD
Gliclazide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000162	0.000615	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000162	0.00153	CbGpPWpGaD
Gliclazide—Anxiety—Prednisone—multiple sclerosis	0.000162	0.000615	CcSEcCtD
Gliclazide—Insomnia—Dexamethasone—multiple sclerosis	0.000162	0.000614	CcSEcCtD
Gliclazide—Insomnia—Betamethasone—multiple sclerosis	0.000162	0.000614	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000161	0.000612	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000161	0.00061	CcSEcCtD
Gliclazide—Paraesthesia—Betamethasone—multiple sclerosis	0.000161	0.00061	CcSEcCtD
Gliclazide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000161	0.00061	CcSEcCtD
Gliclazide—Discomfort—Prednisone—multiple sclerosis	0.000161	0.000609	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—multiple sclerosis	0.000161	0.000609	CcSEcCtD
Gliclazide—Erythema—Methotrexate—multiple sclerosis	0.00016	0.000605	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—multiple sclerosis	0.00016	0.000605	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—LINGO1—multiple sclerosis	0.000159	0.00151	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000158	0.000599	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—MAPK1—multiple sclerosis	0.000158	0.00149	CbGpPWpGaD
Gliclazide—Dyspepsia—Betamethasone—multiple sclerosis	0.000158	0.000598	CcSEcCtD
Gliclazide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000158	0.000598	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—ITGA4—multiple sclerosis	0.000157	0.00149	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	0.000157	0.00148	CbGpPWpGaD
Gliclazide—Urticaria—Triamcinolone—multiple sclerosis	0.000157	0.000594	CcSEcCtD
Gliclazide—Urticaria—Methylprednisolone—multiple sclerosis	0.000156	0.000593	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IFNB1—multiple sclerosis	0.000156	0.00148	CbGpPWpGaD
Gliclazide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000156	0.000591	CcSEcCtD
Gliclazide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000156	0.00059	CcSEcCtD
Gliclazide—Nausea—Mitoxantrone—multiple sclerosis	0.000155	0.000589	CcSEcCtD
Gliclazide—Infection—Prednisone—multiple sclerosis	0.000155	0.000587	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000155	0.000586	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000155	0.000586	CcSEcCtD
Gliclazide—Back pain—Methotrexate—multiple sclerosis	0.000154	0.000586	CcSEcCtD
Gliclazide—Fatigue—Dexamethasone—multiple sclerosis	0.000154	0.000585	CcSEcCtD
Gliclazide—Fatigue—Betamethasone—multiple sclerosis	0.000154	0.000585	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GPC5—multiple sclerosis	0.000154	0.00145	CbGpPWpGaD
Gliclazide—Pain—Dexamethasone—multiple sclerosis	0.000153	0.000581	CcSEcCtD
Gliclazide—Pain—Betamethasone—multiple sclerosis	0.000153	0.000581	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—multiple sclerosis	0.000153	0.00058	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—multiple sclerosis	0.000152	0.000577	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—multiple sclerosis	0.000151	0.000574	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	0.000151	0.00143	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000151	0.000572	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CCL2—multiple sclerosis	0.00015	0.00142	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPC5—multiple sclerosis	0.000149	0.00141	CbGpPWpGaD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000149	0.00141	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000148	0.000562	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—multiple sclerosis	0.000148	0.00056	CcSEcCtD
Gliclazide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000147	0.000559	CcSEcCtD
Gliclazide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000147	0.000559	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000146	0.000555	CcSEcCtD
Gliclazide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000146	0.000555	CcSEcCtD
Gliclazide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000145	0.000551	CcSEcCtD
Gliclazide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000145	0.00055	CcSEcCtD
Gliclazide—Malaise—Methotrexate—multiple sclerosis	0.000144	0.000546	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—multiple sclerosis	0.000143	0.000542	CcSEcCtD
Gliclazide—Urticaria—Betamethasone—multiple sclerosis	0.000142	0.000539	CcSEcCtD
Gliclazide—Urticaria—Dexamethasone—multiple sclerosis	0.000142	0.000539	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000142	0.000539	CcSEcCtD
Gliclazide—Dizziness—Prednisolone—multiple sclerosis	0.000142	0.000538	CcSEcCtD
Gliclazide—Asthenia—Triamcinolone—multiple sclerosis	0.000142	0.000537	CcSEcCtD
Gliclazide—Body temperature increased—Dexamethasone—multiple sclerosis	0.000141	0.000537	CcSEcCtD
Gliclazide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000141	0.000537	CcSEcCtD
Gliclazide—Body temperature increased—Betamethasone—multiple sclerosis	0.000141	0.000537	CcSEcCtD
Gliclazide—Abdominal pain—Betamethasone—multiple sclerosis	0.000141	0.000537	CcSEcCtD
Gliclazide—Asthenia—Methylprednisolone—multiple sclerosis	0.000141	0.000536	CcSEcCtD
Gliclazide—Insomnia—Prednisone—multiple sclerosis	0.000141	0.000535	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—multiple sclerosis	0.00014	0.000531	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	0.00014	0.00132	CbGpPWpGaD
Gliclazide—Pruritus—Triamcinolone—multiple sclerosis	0.00014	0.000529	CcSEcCtD
Gliclazide—Cough—Methotrexate—multiple sclerosis	0.000139	0.000528	CcSEcCtD
Gliclazide—Pruritus—Methylprednisolone—multiple sclerosis	0.000139	0.000528	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—multiple sclerosis	0.000138	0.000525	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—TAGAP—multiple sclerosis	0.000138	0.00131	CbGpPWpGaD
Gliclazide—Dyspepsia—Prednisone—multiple sclerosis	0.000137	0.00052	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—multiple sclerosis	0.000136	0.000515	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—multiple sclerosis	0.000136	0.000515	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—multiple sclerosis	0.000136	0.000515	CcSEcCtD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000136	0.00128	CbGpPWpGaD
Gliclazide—Rash—Prednisolone—multiple sclerosis	0.000135	0.000513	CcSEcCtD
Gliclazide—Dermatitis—Prednisolone—multiple sclerosis	0.000135	0.000512	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000135	0.000512	CcSEcCtD
Gliclazide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000135	0.000511	CcSEcCtD
Gliclazide—Fatigue—Prednisone—multiple sclerosis	0.000134	0.00051	CcSEcCtD
Gliclazide—Headache—Prednisolone—multiple sclerosis	0.000134	0.00051	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—multiple sclerosis	0.000134	0.000509	CcSEcCtD
Gliclazide—Constipation—Prednisone—multiple sclerosis	0.000133	0.000506	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000133	0.00126	CbGpPWpGaD
Gliclazide—Confusional state—Methotrexate—multiple sclerosis	0.000131	0.000498	CcSEcCtD
Gliclazide—Dizziness—Triamcinolone—multiple sclerosis	0.00013	0.000495	CcSEcCtD
Gliclazide—Dizziness—Methylprednisolone—multiple sclerosis	0.00013	0.000494	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.00013	0.00123	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.00013	0.00123	CbGpPWpGaD
Gliclazide—Infection—Methotrexate—multiple sclerosis	0.000129	0.000491	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—multiple sclerosis	0.000128	0.000487	CcSEcCtD
Gliclazide—Asthenia—Dexamethasone—multiple sclerosis	0.000128	0.000487	CcSEcCtD
Gliclazide—Asthenia—Betamethasone—multiple sclerosis	0.000128	0.000487	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—multiple sclerosis	0.000128	0.00121	CbGpPWpGaD
Gliclazide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000128	0.000485	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IFNG—multiple sclerosis	0.000128	0.00121	CbGpPWpGaD
Gliclazide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000128	0.000484	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000127	0.000483	CcSEcCtD
Gliclazide—Nausea—Prednisolone—multiple sclerosis	0.000127	0.000483	CcSEcCtD
Gliclazide—ABCC8—Metabolism—RRM1—multiple sclerosis	0.000127	0.0012	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000127	0.0012	CbGpPWpGaD
Gliclazide—Pruritus—Betamethasone—multiple sclerosis	0.000127	0.00048	CcSEcCtD
Gliclazide—Pruritus—Dexamethasone—multiple sclerosis	0.000127	0.00048	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—multiple sclerosis	0.000127	0.00048	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000126	0.000478	CcSEcCtD
Gliclazide—Vomiting—Triamcinolone—multiple sclerosis	0.000125	0.000476	CcSEcCtD
Gliclazide—Vomiting—Methylprednisolone—multiple sclerosis	0.000125	0.000475	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000124	0.00118	CbGpPWpGaD
Gliclazide—Rash—Triamcinolone—multiple sclerosis	0.000124	0.000472	CcSEcCtD
Gliclazide—Dermatitis—Triamcinolone—multiple sclerosis	0.000124	0.000471	CcSEcCtD
Gliclazide—Rash—Methylprednisolone—multiple sclerosis	0.000124	0.000471	CcSEcCtD
Gliclazide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000124	0.00047	CcSEcCtD
Gliclazide—Urticaria—Prednisone—multiple sclerosis	0.000124	0.00047	CcSEcCtD
Gliclazide—Headache—Triamcinolone—multiple sclerosis	0.000124	0.000469	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—RRM1—multiple sclerosis	0.000124	0.00117	CbGpPWpGaD
Gliclazide—Headache—Methylprednisolone—multiple sclerosis	0.000123	0.000468	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—multiple sclerosis	0.000123	0.000467	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—multiple sclerosis	0.000123	0.000467	CcSEcCtD
Gliclazide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000122	0.000464	CcSEcCtD
Gliclazide—Diarrhoea—Betamethasone—multiple sclerosis	0.000122	0.000464	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000122	0.00116	CbGpPWpGaD
Gliclazide—Hypotension—Methotrexate—multiple sclerosis	0.000122	0.000462	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000122	0.00115	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000122	0.00115	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—IL6—multiple sclerosis	0.000121	0.00115	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—S1PR1—multiple sclerosis	0.000121	0.00114	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00012	0.00114	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000119	0.00113	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000119	0.00045	CcSEcCtD
Gliclazide—Dizziness—Dexamethasone—multiple sclerosis	0.000118	0.000449	CcSEcCtD
Gliclazide—Dizziness—Betamethasone—multiple sclerosis	0.000118	0.000449	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—multiple sclerosis	0.000118	0.000447	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000118	0.00111	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GPC5—multiple sclerosis	0.000117	0.00111	CbGpPWpGaD
Gliclazide—Nausea—Triamcinolone—multiple sclerosis	0.000117	0.000444	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—multiple sclerosis	0.000117	0.000444	CcSEcCtD
Gliclazide—Nausea—Methylprednisolone—multiple sclerosis	0.000117	0.000443	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—multiple sclerosis	0.000116	0.00044	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—multiple sclerosis	0.000116	0.000439	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisone—multiple sclerosis	0.000115	0.000436	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—multiple sclerosis	0.000115	0.000435	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL1B—multiple sclerosis	0.000114	0.00108	CbGpPWpGaD
Gliclazide—Vomiting—Dexamethasone—multiple sclerosis	0.000114	0.000432	CcSEcCtD
Gliclazide—Vomiting—Betamethasone—multiple sclerosis	0.000114	0.000432	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL2—multiple sclerosis	0.000113	0.00107	CbGpPWpGaD
Gliclazide—Rash—Dexamethasone—multiple sclerosis	0.000113	0.000428	CcSEcCtD
Gliclazide—Rash—Betamethasone—multiple sclerosis	0.000113	0.000428	CcSEcCtD
Gliclazide—Dermatitis—Betamethasone—multiple sclerosis	0.000113	0.000428	CcSEcCtD
Gliclazide—Dermatitis—Dexamethasone—multiple sclerosis	0.000113	0.000428	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000112	0.000427	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—multiple sclerosis	0.000112	0.000426	CcSEcCtD
Gliclazide—Headache—Betamethasone—multiple sclerosis	0.000112	0.000425	CcSEcCtD
Gliclazide—Headache—Dexamethasone—multiple sclerosis	0.000112	0.000425	CcSEcCtD
Gliclazide—Asthenia—Prednisone—multiple sclerosis	0.000112	0.000424	CcSEcCtD
Gliclazide—Pain—Methotrexate—multiple sclerosis	0.000111	0.000423	CcSEcCtD
Gliclazide—Pruritus—Prednisone—multiple sclerosis	0.00011	0.000418	CcSEcCtD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00011	0.00104	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000109	0.00103	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000109	0.00103	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLEK—multiple sclerosis	0.000109	0.00103	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—TYK2—multiple sclerosis	0.000108	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2RA—multiple sclerosis	0.000107	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000107	0.00102	CbGpPWpGaD
Gliclazide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000107	0.000407	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000107	0.00101	CbGpPWpGaD
Gliclazide—Diarrhoea—Prednisone—multiple sclerosis	0.000107	0.000404	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000107	0.000404	CcSEcCtD
Gliclazide—Nausea—Dexamethasone—multiple sclerosis	0.000106	0.000403	CcSEcCtD
Gliclazide—Nausea—Betamethasone—multiple sclerosis	0.000106	0.000403	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—MAPK1—multiple sclerosis	0.000105	0.000998	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000105	0.000993	CbGpPWpGaD
Gliclazide—Urticaria—Methotrexate—multiple sclerosis	0.000103	0.000393	CcSEcCtD
Gliclazide—Dizziness—Prednisone—multiple sclerosis	0.000103	0.000391	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—multiple sclerosis	0.000103	0.000391	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—multiple sclerosis	0.000103	0.000391	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—RGS1—multiple sclerosis	0.000103	0.000971	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	0.000102	0.00096	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000101	0.000959	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.0001	0.000946	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.96e-05	0.000942	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.96e-05	0.000942	CbGpPWpGaD
Gliclazide—Vomiting—Prednisone—multiple sclerosis	9.91e-05	0.000376	CcSEcCtD
Gliclazide—Rash—Prednisone—multiple sclerosis	9.83e-05	0.000373	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—multiple sclerosis	9.82e-05	0.000372	CcSEcCtD
Gliclazide—Headache—Prednisone—multiple sclerosis	9.76e-05	0.00037	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—GPR65—multiple sclerosis	9.73e-05	0.00092	CbGpPWpGaD
Gliclazide—Hypersensitivity—Methotrexate—multiple sclerosis	9.6e-05	0.000364	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	9.53e-05	0.000901	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—multiple sclerosis	9.49e-05	0.000898	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.43e-05	0.000892	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	9.35e-05	0.000884	CbGpPWpGaD
Gliclazide—Asthenia—Methotrexate—multiple sclerosis	9.35e-05	0.000354	CcSEcCtD
Gliclazide—Nausea—Prednisone—multiple sclerosis	9.26e-05	0.000351	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—multiple sclerosis	9.22e-05	0.00035	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	9.04e-05	0.000855	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—multiple sclerosis	8.92e-05	0.000844	CbGpPWpGaD
Gliclazide—Diarrhoea—Methotrexate—multiple sclerosis	8.91e-05	0.000338	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CXCL13—multiple sclerosis	8.9e-05	0.000842	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR1—multiple sclerosis	8.9e-05	0.000842	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—multiple sclerosis	8.61e-05	0.000327	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MMP9—multiple sclerosis	8.52e-05	0.000805	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—MAPK1—multiple sclerosis	8.49e-05	0.000803	CbGpPWpGaD
Gliclazide—Vomiting—Methotrexate—multiple sclerosis	8.28e-05	0.000314	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TNF—multiple sclerosis	8.26e-05	0.000781	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—MAPK1—multiple sclerosis	8.23e-05	0.000779	CbGpPWpGaD
Gliclazide—Rash—Methotrexate—multiple sclerosis	8.21e-05	0.000312	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—multiple sclerosis	8.21e-05	0.000311	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	8.19e-05	0.000775	CbGpPWpGaD
Gliclazide—Headache—Methotrexate—multiple sclerosis	8.16e-05	0.00031	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—MAPK1—multiple sclerosis	8.11e-05	0.000767	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—multiple sclerosis	7.77e-05	0.000735	CbGpPWpGaD
Gliclazide—Nausea—Methotrexate—multiple sclerosis	7.74e-05	0.000293	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—TYK2—multiple sclerosis	7.72e-05	0.00073	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SRM—multiple sclerosis	7.69e-05	0.000727	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SELE—multiple sclerosis	7.68e-05	0.000726	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—multiple sclerosis	7.58e-05	0.000717	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.46e-05	0.000705	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.36e-05	0.000696	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	7.36e-05	0.000696	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—BCHE—multiple sclerosis	7.32e-05	0.000692	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	7.23e-05	0.000683	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—BCHE—multiple sclerosis	7.1e-05	0.000671	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SRM—multiple sclerosis	6.91e-05	0.000653	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK1—multiple sclerosis	6.88e-05	0.000651	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—multiple sclerosis	6.67e-05	0.00063	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.59e-05	0.000623	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	6.56e-05	0.000621	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	6.4e-05	0.000605	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL3—multiple sclerosis	6.34e-05	0.0006	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—multiple sclerosis	6.3e-05	0.000596	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SRM—multiple sclerosis	6.3e-05	0.000595	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—multiple sclerosis	6.23e-05	0.000589	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTGER4—multiple sclerosis	6.11e-05	0.000577	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—multiple sclerosis	6.08e-05	0.000575	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PGR—multiple sclerosis	6.01e-05	0.000569	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCR3—multiple sclerosis	5.9e-05	0.000558	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD28—multiple sclerosis	5.84e-05	0.000552	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	5.84e-05	0.000552	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR2—multiple sclerosis	5.74e-05	0.000542	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGA4—multiple sclerosis	5.55e-05	0.000525	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNB1—multiple sclerosis	5.51e-05	0.000521	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP24A1—multiple sclerosis	5.42e-05	0.000513	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP27B1—multiple sclerosis	5.42e-05	0.000513	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—multiple sclerosis	5.4e-05	0.000511	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.3e-05	0.000501	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	5.3e-05	0.000501	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CNR1—multiple sclerosis	5.29e-05	0.000501	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—multiple sclerosis	5.29e-05	0.0005	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—multiple sclerosis	5.01e-05	0.000474	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPC5—multiple sclerosis	4.96e-05	0.000469	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—multiple sclerosis	4.91e-05	0.000465	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—multiple sclerosis	4.91e-05	0.000465	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	4.87e-05	0.00046	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	4.87e-05	0.00046	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—multiple sclerosis	4.82e-05	0.000456	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL10—multiple sclerosis	4.77e-05	0.000451	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.76e-05	0.00045	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—multiple sclerosis	4.68e-05	0.000442	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPC5—multiple sclerosis	4.45e-05	0.000421	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	4.44e-05	0.00042	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	4.44e-05	0.00042	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—multiple sclerosis	4.4e-05	0.000416	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.34e-05	0.00041	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	4.31e-05	0.000408	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—multiple sclerosis	4.27e-05	0.000404	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD86—multiple sclerosis	4.17e-05	0.000394	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RRM1—multiple sclerosis	4.11e-05	0.000388	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL5—multiple sclerosis	4.1e-05	0.000388	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPC5—multiple sclerosis	4.06e-05	0.000384	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SPP1—multiple sclerosis	3.8e-05	0.000359	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2RA—multiple sclerosis	3.79e-05	0.000359	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—POMC—multiple sclerosis	3.78e-05	0.000358	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—multiple sclerosis	3.77e-05	0.000357	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR5—multiple sclerosis	3.7e-05	0.00035	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RRM1—multiple sclerosis	3.69e-05	0.000349	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—POMC—multiple sclerosis	3.67e-05	0.000347	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2RA—multiple sclerosis	3.64e-05	0.000344	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—multiple sclerosis	3.45e-05	0.000326	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	3.36e-05	0.000318	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—multiple sclerosis	3.36e-05	0.000318	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RRM1—multiple sclerosis	3.36e-05	0.000318	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—multiple sclerosis	3.34e-05	0.000316	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	3.3e-05	0.000312	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.19e-05	0.000301	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD80—multiple sclerosis	3.04e-05	0.000288	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—multiple sclerosis	2.89e-05	0.000273	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.86e-05	0.000271	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—multiple sclerosis	2.83e-05	0.000267	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.74e-05	0.000259	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.61e-05	0.000247	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TYK2—multiple sclerosis	2.57e-05	0.000243	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.46e-05	0.000232	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BCHE—multiple sclerosis	2.36e-05	0.000223	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.24e-05	0.000212	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.24e-05	0.000212	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—multiple sclerosis	2.22e-05	0.00021	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—multiple sclerosis	2.14e-05	0.000202	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BCHE—multiple sclerosis	2.12e-05	0.0002	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.04e-05	0.000193	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—multiple sclerosis	2.02e-05	0.000191	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.93e-05	0.000183	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—multiple sclerosis	1.8e-05	0.00017	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—multiple sclerosis	1.73e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—multiple sclerosis	1.7e-05	0.000161	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—multiple sclerosis	1.67e-05	0.000158	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—multiple sclerosis	1.67e-05	0.000158	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—multiple sclerosis	1.63e-05	0.000154	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—multiple sclerosis	1.42e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—multiple sclerosis	1.27e-05	0.00012	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—multiple sclerosis	1.26e-05	0.000119	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—multiple sclerosis	1.22e-05	0.000115	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—multiple sclerosis	1.16e-05	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—multiple sclerosis	1.09e-05	0.000103	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—multiple sclerosis	9.98e-06	9.44e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—multiple sclerosis	9.98e-06	9.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—multiple sclerosis	9.1e-06	8.6e-05	CbGpPWpGaD
